On December 17, 2024, Piramal Pharma’s share price (NSE: PPLPHARMA) traded 6.77% higher at ₹268.25 as of 10:25 AM on the NSE. The stock opened at ₹257.05, higher than the previous close of ₹251.25. Piramal Pharma’s share price has fallen by 1.70% over the last 5 days.
Piramal Pharma’s current price-to-earnings (PE) ratio stands at 51.80, while its price-to-book (PB) ratio is 4.74, according to data from the BSE.
As per news reports, by 2028, the Indian Contract Research, Development, and Manufacturing Organisation (CRDMO) industry is expected to double from FY23 levels, establishing India as a prominent hub for innovator companies seeking partnerships.
Investors believe Piramal Pharma is a standout among its Indian CDMO peers, due to its unique offerings, global manufacturing presence, and end-to-end capabilities.
Piramal Pharma reported strong financial results for the second quarter of FY25, with net profit rising 350% year-on-year to ₹22.59 crore, up from ₹5.02 crore in Q2 FY24.
Revenue from operations grew by 17.3%, reaching ₹2,241.75 crore, compared to ₹1,911.38 crore in the same period last year.
The company’s EBITDA increased by 29%, rising to ₹341.61 crore from ₹265.64 crore, with the EBITDA margin improving to 15.2% from 13.9% year-on-year.
Piramal Pharma’s CDMO business benefited from increased demand for innovation projects. The company also announced an $80 million expansion plan at its Lexington facility, expected to be completed by FY27.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
Published on: Dec 17, 2024, 10:43 AM IST
We're Live on WhatsApp! Join our channel for market insights & updates